Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
about
Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and GammaPharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs).The role of Wnt signaling in the development of Alzheimer's disease: a potential therapeutic target?Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes.Role of vascular risk factors and vascular dysfunction in Alzheimer's disease.Lipid rafts participate in aberrant degradative autophagic-lysosomal pathway of amyloid-beta peptide in Alzheimer's diseaseCerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairmentA multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide researchPathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellumDepletion of Beclin-1 due to proteolytic cleavage by caspases in the Alzheimer's disease brainBrain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's diseaseInvestigating the association of ApoE genotypes with blood-brain barrier dysfunction measured by cerebrospinal fluid-serum albumin ratio in a cohort of patients with different types of dementiaDementia and Alzheimer's disease: a new direction.The 2010 Jay L. Foster Memorial Lecture.Insight into the Protein Composition of Immunoglobulin Light Chain Deposits of Eyelid, Orbital and Conjunctival Amyloidosis.Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy.Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approachesAssociation of plasma and cortical amyloid beta is modulated by APOE ε4 statusInsulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's diseaseAlzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}Cerebrovascular smooth muscle actin is increased in nondemented subjects with frequent senile plaques at autopsy: implications for the pathogenesis of Alzheimer disease.Hygiene and the world distribution of Alzheimer's disease: Epidemiological evidence for a relationship between microbial environment and age-adjusted disease burdenNeuronal nicotinic acetylcholine receptor-cholesterol crosstalk in Alzheimer's disease.Oxidative stress and β-amyloid protein in Alzheimer's disease.Alzheimer disease and cellular mechanisms of memory storage.Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.Dickkopf 3 (Dkk3) Improves Amyloid-β Pathology, Cognitive Dysfunction, and Cerebral Glucose Metabolism in a Transgenic Mouse Model of Alzheimer's Disease.Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer's disease mouse model.A high cholesterol diet given to apolipoprotein E-knockout mice has a differential effect on the various neurotrophin systems in the hippocampus.Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
P2860
Q28075617-5396140E-C248-4F9B-B9B8-01F7B98BFCACQ33372606-97136D27-DC0E-4A52-B783-C429016DF0B5Q33634629-445E36F3-329B-4F6A-940D-FE8C2186DC24Q33976938-C199E624-EE16-45A9-A9E5-9DC286E19985Q34055011-8D7D051B-0EB7-4115-AD1A-3DF50B12D789Q34096338-07CF7E78-8A55-42CF-A040-211AC3FBA654Q34175825-EDD1F586-88D6-4E43-ADF0-9367710EFF27Q34273807-D3AC153F-A76D-4919-8904-2C6C33E2F9D3Q34502082-7073939E-71F4-4621-A7D6-FF923921CF22Q34630346-6B68C2D8-B548-4A59-97D9-B8B7AD021069Q34733374-35FE8BA2-ED2F-452D-A915-A5CCC215B429Q34802970-38342689-41F2-4EDB-AB85-14AE0A7A5373Q35080927-3F67A990-43AB-456C-AA75-E2B3095B845DQ35394390-48A9993A-F82A-41B6-83C4-DB391C19FCE2Q35820992-E3F6FEC8-2629-4A56-992C-C9B60AA54AD2Q36501212-8678DFC2-B0BF-4C55-9AC5-662CA01E5B83Q36530897-D33C14AC-B015-458B-949B-D5E429F2ACB5Q37112462-9BDB0237-7414-40FC-90BA-EEAA8DC4D4A6Q37208538-A88F85AA-3287-47F9-9769-9605AB88FCBEQ37253310-68228DAC-10C7-40FE-B3C3-8CCD8154C2C4Q37253971-8F5F5AF2-DF39-48F0-A97A-9F9C8A35A67FQ37319974-BB32D7C6-F33B-45E3-AF75-6404DF2F65DCQ37404439-C4C53D60-A52C-4311-A80F-EF4F345B7E92Q37633047-E8E2B644-90A8-4EC2-AC41-8B055B237ED7Q37928994-0E6704C4-DE92-4D63-A179-8D53CDCAD973Q38184387-AEAE5095-8FDE-4A3D-A2A1-13168C4F5B2CQ39135845-5FF8D51C-E0B0-45ED-957A-8805064B2402Q47968064-202CB38F-CD2D-4BE2-A862-89E784B3A937Q48701919-12B7F3F7-FDB9-43DC-8C33-9A6A79BB70ABQ48957935-57E7ACD9-7055-4265-8464-755CE9B72C9DQ58729492-03B24BA2-03E7-416C-BD94-929B198D2B86
P2860
Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Apolipoprotein E, amyloid-beta ...... eability in Alzheimer disease.
@en
Apolipoprotein E, amyloid-beta ...... eability in Alzheimer disease.
@nl
type
label
Apolipoprotein E, amyloid-beta ...... eability in Alzheimer disease.
@en
Apolipoprotein E, amyloid-beta ...... eability in Alzheimer disease.
@nl
prefLabel
Apolipoprotein E, amyloid-beta ...... eability in Alzheimer disease.
@en
Apolipoprotein E, amyloid-beta ...... eability in Alzheimer disease.
@nl
P2860
P1476
Apolipoprotein E, amyloid-beta ...... eability in Alzheimer disease.
@en
P2093
Conrad E Johanson
John E Donahue
P2860
P304
P356
10.1097/NEN.0B013E31816A0DC8
P577
2008-04-01T00:00:00Z